Inhibitor treatment in haemophilias A and B: Summary statement for the 2006 international consensus conference

Haemophilia

Volumn 12, Issue SUPPL. 6, 2006, Pages 1-7

  Berntorp, Erik ^a   Shapiro, A ^b   Astermark, J ^a   Blanchette, V S ^c   Collins, P W ^d   Dimichele, D ^e   Escuriola, C ^f   Hay, C R M ^g   Hoots, W K ^h   Leissinger, C A ⁱ   Negrier, C ^j   Oldenburg, J ^k   Peerlinck, K ^l   Reding, M T ^m   Hart, C ⁿ  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b INDIANA HEMOPHILIA AND THROMBOSIS CENTER   (United States)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^g MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^h UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

ⁱ TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITÉ DE LYON   (France)

^k UNIVERSITY HOSPITAL BONN   (Germany)

^l UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^m UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

ⁿ InforMEDical Inc   (United States)

more..

Author keywords

Diagnosis; Guidelines; Haemophilia; Inhibitors; Treatment

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; DESMOPRESSIN; IMMUNOGLOBULIN G ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RITUXIMAB;

ANTIBODY DETECTION; ANTIBODY PRODUCTION; ARTHROPATHY; BIOASSAY; BLEEDING; CLINICAL TRIAL; COHORT ANALYSIS; CONFERENCE PAPER; DISEASE SURVEILLANCE; DRUG DOSE REGIMEN; EVIDENCE BASED MEDICINE; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; HEALTH CARE COST; HEMOPHILIA A; HEMOPHILIA B; HUMAN; IMMUNOADSORPTION; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; INTERNATIONAL COOPERATION; MEDICAL RESEARCH; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; SYNOVECTOMY; VASCULAR ACCESS;

BLOOD COAGULATION FACTOR INHIBITORS; CONSENSUS DEVELOPMENT CONFERENCES; GENETIC SCREENING; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; PRACTICE GUIDELINES; RISK FACTORS;

EID: 33750988816     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2006.01359.x     Document Type: Conference Paper

References (0)